ArticleStem cell reports2017
Polysaccharides from Ganoderma lucidum Promote Cognitive Function and Neural Progenitor Proliferation in Mouse Model of Alzheimer's Disease.
Article in Stem cell reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 150 citations in OpenAlex.
- Mechanism of Ganoderma lucidum polysaccharides in the mangement of diabetes and its complications.Frontiers in pharmacology · 2026Pooled it
- Trial
- Impact of Hericium erinaceus and Ganoderma lucidum metabolites on AhR activation in neuronal HT-22 cells.Pharmacological reports : PR · 2025Article
- Investigating the Neuroprotective, Hepatoprotective, and Antimicrobial Effects of Mushroom Extracts.International journal of molecular sciences · 2025Article
- UnCOT-AD: Unpaired Cross-Omics Translation Enables Multi-Omics Integration for Alzheimer's Disease Prediction.Briefings in bioinformatics · 2025Article
- Unlocking the therapeutic potential of bioactive compounds in3 Biotech · 2025Review
- Polysaccharides from Ganoderma lucidum attenuate cognitive impairment in 5xFAD mice by inhibiting oxidative stress and modulating mitochondrial dynamics via the Nrf2/antioxidative axis activation.Metabolic brain disease · 2025Article
- Survival Benefits ofRecent patents on anti-cancer drug discovery · 2025Article
- Intranasal administration ofFrontiers in pharmacology · 2025Article
- Food Functional Factors in Alzheimer's Disease Intervention: Current Research Progress.Nutrients · 2024Review
- The Biological Activity ofMolecules (Basel, Switzerland) · 2024Review
- Optimization of the Preparation Process of Glucuronomannan Oligosaccharides and Their Effects on the Gut Microbiota in MPTP-Induced PD Model Mice.Marine drugs · 2024Article
- Protective effect of Ganoderma lucidum-fermented crop extracts against hydrogen peroxide- or β-amyloid-induced damage in human neuronal SH-SY5Y cells.BMC complementary medicine and therapies · 2024Article
- Unlocking the Power: New Insights into the Anti-Aging Properties of Mushrooms.Journal of fungi (Basel, Switzerland) · 2024Review
- Unraveling the web of defense: the crucial role of polysaccharides in immunity.Frontiers in immunology · 2024Review
- Unveiling the Therapeutic Potentials of Mushroom Bioactive Compounds in Alzheimer's Disease.Foods (Basel, Switzerland) · 2023Review
- Multiple Metabolites Derived from Mushrooms and Their Beneficial Effect on Alzheimer's Diseases.Nutrients · 2023Review
- The Potential of Edible and Medicinal Resource Polysaccharides for Prevention and Treatment of Neurodegenerative Diseases.Biomolecules · 2023Review
- Plant polysaccharides utilized by gut microbiota: New players in ameliorating cognitive impairment.Journal of traditional and complementary medicine · 2023Review
- Mechanism, prevention and treatment of cognitive impairment caused by high altitude exposure.Frontiers in physiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Promoting neurogenesis is a promising strategy for the treatment of cognition impairment associated with Alzheimer's disease (AD). Ganoderma lucidum is a revered medicinal mushroom for health-promoting benefits in the Orient. Here, we found that oral administration of the polysaccharides and water extract from G. lucidum promoted neural progenitor cell (NPC) proliferation to enhance neurogenesis and alleviated cognitive deficits in transgenic AD mice. G. lucidum polysaccharides (GLP) also promoted self-renewal of NPC in cell culture. Further mechanistic study revealed that GLP potentiated activation of fibroblast growth factor receptor 1 (FGFR1) and downstream extracellular signal-regulated kinase (ERK) and AKT cascades. Consistently, inhibition of FGFR1 effectively blocked the GLP-promoted NPC proliferation and activation of the downstream cascades. Our findings suggest that GLP could serve as a regenerative therapeutic agent for the treatment of cognitive decline associated with neurodegenerative diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.